|
|
|
|
|
21.02.26 - 15:03
|
AnorTech Grants Stock Options (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Feb. 21, 2026 (GLOBE NEWSWIRE) -- ANORTECH INC. (“AnorTech” or the “Company”) (TSX Venture Exchange “ANOR”; OTCQB “ANORF”) has granted incentive stock options under the Company's stock option plan to directors, employees and consultants to purchase a total of 5,150,000 shares at a price of $0.10 per share. The options vest over 18 months and have a term of five years, subject to the policies of the TSX Venture Exchange....
|
|
|
|
|
|
|
|
|
21.02.26 - 00:03
|
K2 Capital Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing on February 25, 2026 (GlobeNewswire EN)
|
|
|
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- K2 Capital Acquisition Corp. (the "Company") today announced that, commencing on February 25, 2026, holders of the 13,800,000 units (the “Units”) sold in the Company's initial public offering (the “Offering”), including Units sold upon full exercise of the underwriters' over-allotment option, may elect to separately trade the Class A ordinary shares and rights included in the Units. Any Units not separated will continue to trade on the NASDAQ Global Market (“NASDAQ”) under the symbol “KTWOU.” Any underlying Class A ordinary shares and rights that are separated will trade on the NASDAQ under the symbols “KTWO” and “KTWOR,” respectively. Holders of Units will need to have their brokers contact the Company's transfer agent, VStock Transfer, in order to separate the holders' Units into Class A ordinary shares and rights....
|
|
|
|
|
20.02.26 - 23:24
|
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment (GlobeNewswire EN)
|
|
|
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds ("PsyLabs") has exercised its rights under a previously disclosed put option agreement (the "Put Option Agreement"), pursuant to which Psyence BioMed will make an equity investment in PsyLabs at a fair market value determined in accordance with the terms of the Put Option Agreement....
|
|
|
20.02.26 - 23:18
|
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on February 19, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 3,600 shares of Iovance's common stock to two new, non-executive employees....
|
|
|
|
|
|
|
|
|
|
|
20.02.26 - 23:03
|
AirBoss to Release 4th Quarter and FY 2025 Earnings on March 4, 2026 (GlobeNewswire EN)
|
|
|
NEWMARKET, Ontario, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AirBoss of America Corp. (TSX: BOS) (OTCQX:ABSSF) (the “Company” or “AirBoss”) today announced that it will release its fourth quarter and unaudited full year 2025 results after markets close on March 4, 2026. The release will be followed by a conference call to discuss the results on Thursday, March 5, 2026, at 9:00 am ET. The Company will file its audited annual consolidated financial statements and related management's discussion and analysis for the year ended December 31, 2025 following the conclusion of the audit and in accordance with applicable securities laws....
|
|
|
|
|
|
|
20.02.26 - 22:33
|
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
NOVATO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 22,917 restricted stock units of the company's common stock to six newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of February 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
20.02.26 - 22:33
|
Founder Group Limited Receives NASDAQ Notification Regarding Minimum Publicly Held Shares Deficiency (GlobeNewswire EN)
|
|
|
SELANGOR, Malaysia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Founder Group Limited (Nasdaq: FGL) (“FGL” or the “Company”), announced today that on February 17, 2026, the Company received a letter from the Listing Qualifications Department of Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that since it no longer meets the minimum 500,000 publicly held shares requirement under Nasdaq Listing Rule 5550(a)(4) for the Nasdaq Capital Market, it no longer complies with the Listing Rules for continued listing....
|
|
|
20.02.26 - 22:33
|
iPower Reports Fiscal Q2 2026 Results and Completes Strategic Operating Reset (GlobeNewswire EN)
|
|
|
RANCHO CUCAMONGA, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- iPower Inc. (Nasdaq: IPW) (“iPower” or the “Company”) today reported financial results for the fiscal second quarter ended December 31, 2025. Revenue was $7.1 million, reflecting the Company's deliberate supply chain restructuring and transition to predominantly U.S.-based sourcing during the quarter, while gross profit was $3.1 million and gross margin remained strong at 44.0%. Total operating expenses declined 28% year-over-year to $5.6 million compared to the quarter ended December 31, 2024. Net loss attributable to iPower was $1.2 million, or $(1.08) per share. The Company reported $2.0 million of cash and cash equivalents, $2.2 million of restricted cash, and approximately $2.2 million of digital assets....
|
|
|
20.02.26 - 22:33
|
Parex Resources Announces Nomination of Six Directors to GeoPark′s Board (GlobeNewswire EN)
|
|
|
CALGARY, Alberta, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT), which has an approximate 11.8% ownership position in GeoPark Limited (“GeoPark”) (NYSE: GPRK), announced today that it has nominated six highly qualified director candidates for election to GeoPark's Board of Directors (the “GeoPark Board”) at its upcoming 2026 Annual Meeting of Shareholders (the “Annual Meeting”). Each of the nominees is independent of both GeoPark and Parex under applicable securities laws and stock exchange rules....
|
|